Comparison of WHO classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors

American Journal of Surgical Pathology

Volumn 37, Issue 6, 2013, Pages 853-859

  Liu, Ta Chiang ^a   Hamilton, Nicholas ^b   Hawkins, William ^b   Gao, Feng ^b   Cao, Dengfeng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AJCC staging; ENETS staging; Hochwald grading system; Ki 67 proliferation index; Pancreatic neuroendocrine tumor; WHO classification

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; CLASSIFICATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; WORLD HEALTH ORGANIZATION;

DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 84880150788     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31827fcc18     Document Type: Article

References (23)

1. Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-427.
2. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
3. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642.
4. Klimstra DS, Arnold R, Capella C, et al. Tumours of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer (IARC); 2010:279-337.
5. Exocrine and Endocrine Pancreas. AJCC Cancer Staging Manual. New York, NY: Springer; 2010:241-249.
6. Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764-777.
7. von Herbay A, Sieg B, Schurmann G, et al. Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut. 1991;32:949-953.
8. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27:1124-1134.
9. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
10. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282-288.
11. Heitz P, Komminoth P, Perren A, et al. Tumours of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz P, et al, eds. Pathology and Genetics of Endocrine Organs. Lyon: International Agency for Research on Cancer (IARC); 2004:177-182.
12. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
13. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609-5615.
14. Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044-3049.
15. Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321-325.
16. Goodell PP, Krasinskas AM, Davison JM, et al. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol. 2012;137:576-582.
17. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30: 560-574.
18. Corbo V, Dalai I, Scardoni M, et al. MEN1 in Pancreatic Endocrine Tumors: Analysis of Gene and Protein Status in 169 Sporadic Neoplasms Reveals Alterations in the Vast Majority of Cases. Endocr Relat Cancer. 2010;17:771-783.
19. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16: 1806-1810.
20. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113: 1807-1843.
21. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
22. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333: 425.
23. de Wilde RF, Edil BH, Hruban RH, et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9:199-208.